You've been on Wegovy for 6 months. Down 22 pounds. Plateauing.
Your friend just started Mounjaro and is losing faster. Your Reddit feed is suddenly half "should I switch to tirzepatide" posts. Your insurance just denied a Mounjaro prior auth.
And then someone in the comments mentions a personal-import option for cheap tirzepatide.
Most of what's being said in those threads is wrong. Let me lay out what the head-to-head trial actually showed, what the 2024 compounding crackdown actually closed, and where my own bias as the author of this article distorts the recommendation.
We don't route tirzepatide. Read this with that in mind.
LiberaCure routes generic semaglutide — both oral (Sembolic, by Torrent) and injectable (Noveltreat, by Sun Pharma). That's the lane we have a financial reason to push you toward.
We do not route tirzepatide. There is no Indian generic tirzepatide as of April 2026 — Lilly's manufacturing exclusivity, US patent (running through ~2036), and the Indian regulatory pathway haven't opened the molecule for generic export yet. Not "we chose not to carry it." It does not exist as a personal-import product.
So when you read what follows, factor in: an article written by a semaglutide router has structural reasons to underweight tirzepatide. I'm flagging it now and we'll come back to it twice more.
The head-to-head data still says what it says, even with my bias.
The molecule difference, plainly
Semaglutide (Wegovy, Ozempic, Rybelsus — all Novo Nordisk): a single GLP-1 receptor agonist. Mimics the gut hormone glucagon-like peptide 1. One target.
Tirzepatide (Mounjaro, Zepbound — both Eli Lilly): a dual GIP/GLP-1 receptor agonist. Hits GLP-1 the same way semaglutide does, plus a second receptor — GIP (glucose-dependent insulinotropic polypeptide). Two targets, one molecule.
Why GIP matters: GIP appears to amplify GLP-1's appetite-suppression effect and improve insulin sensitivity beyond what GLP-1 alone delivers. It's the dual mechanism that the Mounjaro marketing is selling, and the trial data backs the mechanism — at least at the efficacy endpoint.
Tirzepatide is also weekly injection only. There is no oral tirzepatide. (Lilly has an oral GLP-1 in pipeline — orforglipron — but it's a different molecule, not tirz in pill form.)
SURMOUNT-5: the head-to-head trial
For four years, every "is tirz better than sema" thread was speculative because the two drugs had only been studied separately. That changed in May 2025.
SURMOUNT-5 (Aronne et al., NEJM 2025, published online May 11, 2025) is the first major head-to-head trial. 751 adults with obesity but without diabetes, randomized 1:1 to either tirzepatide max-tolerated dose (10 or 15mg weekly) or semaglutide max-tolerated dose (1.7 or 2.4mg weekly). 72 weeks of treatment.
Results:
| Endpoint at week 72 | Tirzepatide | Semaglutide | Difference |
|---|---|---|---|
| Mean weight loss (% body weight) | ~20.2% | ~13.7% | ~6.5 percentage points in favor of tirz |
| ≥5% weight loss | ~92% | ~77% | tirz higher |
| ≥15% weight loss | ~65% | ~40% | tirz substantially higher |
| ≥25% weight loss | ~32% | ~16% | tirz roughly double |
This is the cleanest tirz-vs-sema result we have. Tirzepatide produces meaningfully more weight loss at the maximum tolerated dose, and the gap widens at the deeper-loss percentiles. If your goal is the deepest possible weight loss, tirz wins.
For context, this matches the separate-trial data:
- STEP 1 (Wilding 2021, NEJM 2021;384:989): semaglutide 2.4mg, 14.9% mean loss at 68 weeks
- SURMOUNT-1 (Jastreboff 2022, NEJM 2022;387:205): tirzepatide 15mg, 20.9% mean loss at 72 weeks
Both separate trials and the head-to-head agree: tirz produces ~6 percentage points more weight loss at maximum dose.
The side effect comparison
Here's where the conventional wisdom is wrong. People assume "stronger drug = worse side effects." With tirzepatide, that's not what the data shows.
Across SURMOUNT-1 and SURMOUNT-5:
| Side effect, 15mg weekly | Tirzepatide | Semaglutide 2.4mg |
|---|---|---|
| Nausea | ~29% | ~44% |
| Diarrhea | ~23% | ~30% |
| Constipation | ~17% | ~24% |
| Vomiting | ~13% | ~24% |
| Discontinued for side effects | ~6% | ~6-7% |
Source: Aronne 2025 SURMOUNT-5 supplementary table 2 + Jastreboff 2022 SURMOUNT-1 table 2.
Tirzepatide patients reported lower nausea, vomiting, and overall GI burden than semaglutide patients at maximum dose. The discontinuation rate is roughly the same.
Why? Best mechanistic guess: GIP signaling appears to attenuate the nausea pathway that GLP-1 alone triggers. The dual molecule may be better tolerated, not worse, at equivalent weight-loss efficacy.
Caveat: titration matters. The early weeks of tirzepatide titration (especially weeks 1-4 at 2.5mg) can be heavier on nausea than the equivalent semaglutide ramp, partly because the dose escalation steps are larger. People who switched from semaglutide to tirzepatide and reported "tirz wrecked me" usually did so in weeks 2-6, before the steady-state tolerance kicks in.
The settled-state side effect profile favors tirzepatide. The titration friction can run the other direction. Both are true.
Where the access lane gets ugly
Tirzepatide's pricing problem is harsher than semaglutide's, because the alternatives are thinner.
| Source | Tirzepatide cash price | Semaglutide cash equivalent |
|---|---|---|
| Brand Mounjaro / Zepbound (Lilly US list) | $1,000-1,200/mo | Wegovy: $1,349-1,800/mo list |
| LillyDirect (Lilly's self-pay program, 2024 launch) | $349-499/mo (vials, not autoinjector) | NovoCare Direct: $349/mo (cut from $499 in late 2025) |
| Hims tirzepatide brand | $1,899/mo | Hims sema: similar tier |
| Hims tirzepatide vial (post-compounding-crackdown personalized prescribing) | $299/mo | n/a equivalent |
| US compounding pharmacy tirzepatide | mostly closed October 2024 | mostly closed February 2025 |
| LiberaCure-routed generic tirzepatide | does not exist (no Indian generic) | $80-150/mo (Noveltreat by Sun Pharma) |
Read the bottom rows carefully.
The 2024 FDA compounding crackdown closed cheap US compounded tirzepatide on a different timeline than semaglutide. Tirzepatide shortage was declared resolved October 2024, which removed the FDA's 503A shortage exemption (a rule that lets US compounding pharmacies legally make copies of brand drugs while the brand is in shortage) and made compounding broadly impermissible — earlier than the semaglutide closure (February 2025). For the period 2022-October 2024, US patients could get compounded tirzepatide at $200-400/mo. That lane is mostly gone.
The personal-import lane that solves this for semaglutide does not yet exist for tirzepatide. Indian manufacturers (Sun Pharma, Dr. Reddy's, Torrent, Cipla) launched generic semaglutide in March 2026 the same month as the Indian patent expiry. The tirzepatide patent runs longer in India, and no equivalent generic launch has happened. As of April 2026: zero Indian generic tirzepatide on personal-import shelves.
This is the crux of the honest comparison. Tirzepatide wins efficacy. Semaglutide wins access — by a lot — because the generic lane only exists for semaglutide right now.
The decision tree, by your actual constraint
Forget the trial data for a second. The right molecule for you depends on which constraint binds first.
If you have insurance that covers Wegovy or Zepbound and the prior auth went through: the deciding factor is what your plan covers. Both work. Tirzepatide loses ~6 percentage points more weight. If your plan covers tirzepatide, take tirzepatide. If only sema, take sema. The price-to-you is comparable.
If you're paying cash and brand prices are sustainable for you: start at brand. LillyDirect runs $349-499/mo for Zepbound vials, which is the cheapest legitimate Lilly route. NovoCare Direct runs $349/mo for Wegovy (cut from $499 in late 2025). Pick on tolerability and your physician's read, not on price — the prices are roughly comparable at this tier, with NovoCare slightly cheaper now. Most people still pick tirzepatide here on efficacy grounds.
If brand-tier pricing is unsustainable and you're cost-constrained: this is the painful case. There's no cheap tirzepatide lane right now. Compounded tirzepatide is mostly gone. There's no Indian generic. Your remaining options:
- Accept the cost gap and pay $300-500/mo for LillyDirect Zepbound vials (still cheap relative to brand).
- Use telehealth (Hims, Eden, Ro Body) for the personalized-prescribing tirzepatide lane that survived the 503A crackdown — runs $200-400/mo, supply varies, the legal frame is narrower than it was.
- Switch the molecule. Generic semaglutide via personal-import lands at $80-150/mo. You'll lose ~6 percentage points of weight-loss efficacy versus what tirzepatide would have given you, but the cost gap is 5-15x. Whether that's worth it depends on your goal.
If you're already on semaglutide and considering switching to tirzepatide for the extra ~6%: be careful what you optimize. SURMOUNT-5 enrolled people starting fresh, not people switching mid-treatment. Switching incurs a fresh titration with the early-weeks GI burden and the reset of your tolerance. The honest answer is: if semaglutide is working and you're tolerating it, the marginal upgrade to tirzepatide isn't free. If you've stalled at sema 2.4mg for 8+ weeks and you have insurance / cash for tirz, it's reasonable. Don't switch on hype alone.
If you're chasing personal-import tirzepatide: there is no legitimate personal-import tirzepatide lane right now. The "generic tirzepatide" listings on personal-import sites are almost all non-pharmaceutical research-chemical "TIRZ" peptides sold for "research use only" — different supply chain, different regulatory frame, no quality standard. The FDA has issued Warning Letters and injunctions against research-peptide vendors marketing tirzepatide for human use during 2024-2025 (e.g., the agency's December 2023 letter to a major peptide reseller, followed by ongoing 2024-2025 enforcement against compounders and resellers operating outside the 503A exemption). We don't route those. Most legitimate personal-import operators don't either.
The metaphor: tirzepatide is the new iPhone, semaglutide is the one with a generic
The new iPhone is genuinely better. Faster chip. Better camera. Some of the upgrade is real.
The generic Android is a fraction of the price, runs the same apps, and works fine. Not as polished. Maybe 80% of the experience.
You can argue all day about whether the iPhone upgrade is worth 10x. But the argument is dishonest if you skip a fact: the generic Android exists. Tirzepatide has no generic alternative right now. You either pay full Lilly price or you don't take it.
That's the tirzepatide / semaglutide situation today. Tirz is the new iPhone with no generic version available yet. Sema has a generic at a fraction of the price (~1/15 in the cheapest lane). Comparing them on efficacy alone hides the lane that actually exists.
When the Indian generic tirzepatide lane opens — which will happen, probably 2027-2030 depending on how the patent challenges resolve — the analysis flips. Until then, the comparison is asymmetric.
What to do this month
If you've never started GLP-1: read our Wegovy vs generic semaglutide pricing breakdown for the cost reality. If you can afford LillyDirect ($349-499/mo) or have insurance that covers it, start at Zepbound — the efficacy edge is real and you're not yet locked into tolerance to a different molecule. If you cannot, generic semaglutide is the cheap entry point.
If you're on Wegovy and considering Zepbound switch: don't switch unless you've stalled for 8+ weeks at 2.4mg and you have a clear cost / insurance lane to tirz. Switching costs a fresh titration. Switching on hype has burned a lot of people in the past 12 months.
If you've been compounded-tirzepatide-pilled (you got cheap tirz from a US compounder in 2023-2024 and now your supplier evaporated): your cheapest legitimate options are LillyDirect Zepbound vials ($349/mo) or surviving personalized-prescribing telehealth tirzepatide lanes (Hims vial $299/mo). The lane you had is gone. Plan for $300-500/mo, not $200.
If you're considering personal-import tirzepatide because you saw an ad: don't. There's no legitimate generic. Read our compounding crackdown article for what closed and why the "research peptide" sites are not the same lane.
If you've decided sema is the right fit and want to reduce cost: that's the lane LiberaCure does route. See our GLP-1 pillar guide for the full molecule + dose + format decision tree.
For reference on what we route: payment is crypto-only (BTC, USDT TRC-20, LTC, XMR, ETH via NOWPayments). Lead time 2 weeks standard, 2-4 weeks with customs variance. Cold-chain (2-8°C) handling is the supplier's responsibility end-to-end on the injection lane. Reship once free if tracking shows lost in transit. Second reship also free. Crypto refund on third failure.
A note on bias.
We sell sema, not tirz. Read this with that in mind.
LiberaCure routes orders to licensed personal-import pharmacies. Sembolic (oral generic semaglutide, by Torrent Pharma) and Noveltreat (injectable generic semaglutide pens, by Sun Pharma) are two of the products we ship in this category. There is no Indian generic tirzepatide available as of April 2026 — Lilly's patent runs longer there, and no equivalent generic lane has opened. So we route only one side of this comparison.
That gives me a financial reason to want this article to lead you toward semaglutide rather than tirzepatide. I tried to write the trial data the other way — tirzepatide is more effective in head-to-head testing, the side effect profile is comparable or better at steady state, and if you can afford it via insurance or LillyDirect, it is the more potent molecule. The reason cost-constrained patients end up on semaglutide is the access lane asymmetry, not the molecule's inferiority.
Read this with that in mind. The protocol above is what I'd tell a friend, not what maximizes reorder rate.
Sources:
- Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025; published online May 11, 2025. (Head-to-head trial: tirz 15mg ~20.2% vs sema 2.4mg ~13.7% mean weight loss at 72 weeks.)
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. PMID 35658024
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021;384:989-1002. PMID 33567185
- Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503-515. (Earlier head-to-head in T2DM.)
- FDA Drug Shortages Database — tirzepatide resolved October 2024; semaglutide resolved February 21, 2025 (503A grace through April 22, 2025; 503B through May 22, 2025).
- Eli Lilly LillyDirect self-pay pricing for Zepbound vials, accessed April 2026 ($349-499/mo).
- Novo Nordisk NovoCare Direct self-pay pricing for Wegovy, accessed April 2026 ($349/mo, cut from $499 in late 2025).
- Hims Mounjaro / Zepbound brand and vial pricing, accessed April 2026.
- US patent and Indian patent landscape for tirzepatide (Eli Lilly, expected expiry 2036+ in US; Indian generic launch not yet authorized as of April 2026).
— LiberaCure editorial. We route generic medication through licensed personal-import pharmacies. We don't dispense, prescribe, or warehouse. Read more about why.